Cargando…

P09-02. Selection pressure of neutralizing antibodies and viral escape continues in late stages of the disease

Detalles Bibliográficos
Autores principales:	Rusert, P, Krarup, A, Joos, B, Uhr, T, Weber, J, Herbert, K, Guenthard, HF, Trkola, A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767599/ http://dx.doi.org/10.1186/1742-4690-6-S3-P115

Ejemplares similares

P02-09. Dissecting the interference of endotoxins with HIV infection of primary CD4 T cell
por: Krarup, A, et al.
Publicado: (2009)

Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent
por: Reh, Lucia, et al.
Publicado: (2015)

P04-40. Dissecting pre- and post-attachment activity of HIV-1 entry inhibitors and neutralizing antibodies
por: Berlinger, L, et al.
Publicado: (2009)

Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
por: Rusert, Peter, et al.
Publicado: (2011)

MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
por: Ruprecht, Claudia R., et al.
Publicado: (2011)

SIGNIFICANCE OF BIVALENCE OF ANTIBODY IN VIRAL NEUTRALIZATION
por: Rosenstein, Robert W., et al.
Publicado: (1971)

Complete mapping of viral escape from neutralizing antibodies
por: Doud, Michael B., et al.
Publicado: (2017)

Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters
por: Brandenberg, Oliver F., et al.
Publicado: (2017)

P09-10. Impact of CTL escape mutations in HIV-1 Nef on viral replication
por: Oniangue-Ndza, C, et al.
Publicado: (2009)

Conformation-dependent recognition of HIV Gp120 by DARPins provides novel possibilities to develop distinct HIV entry inhibitors
por: Mann, AM, et al.
Publicado: (2012)

Structural Basis of HCV Neutralization by Human Monoclonal Antibodies Resistant to Viral Neutralization Escape
por: Krey, Thomas, et al.
Publicado: (2013)

P09-12. Autologous neutralizing antibodies in early subtype C HIV-1 infection target variable regions of envelope and drive multiple pathways of viral escape
por: Rong, R, et al.
Publicado: (2009)

Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage
por: Reh, Lucia, et al.
Publicado: (2018)

P09-07. Balancing reversion of CTL and neutralizing antibody escape mutations within HIV-1 Env upon transmission
por: Peut, V, et al.
Publicado: (2009)

P03-07. Autologous neutralizing antibodies that select viral escape variants emerge late after SIV infection of rhesus monkeys
por: Yeh, WW, et al.
Publicado: (2009)

Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity
por: Kadelka, Claus, et al.
Publicado: (2018)

Summary of the meeting of the PS Management Board held on 02.09.2002
por: Kehrer, T
Publicado: (2002)

Professor Stefan Hohmann (08.09.1956–02.07.2021)
por: Nielsen, Jens, et al.
Publicado: (2022)

Reply to correspondence ‘Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a “stochastic” process’ by Gonzalez et al., Retrovirology 2017
por: Oberle, Corinna S., et al.
Publicado: (2017)

Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope
por: Anthony, Colin, et al.
Publicado: (2017)

P09-04. Charge changes in the alpha2-helix in the C3 region of the HIV-1 subtype C envelope mediate neutralization escape
por: Moore, PL, et al.
Publicado: (2009)

P09-06. HIV-1 escape from broadly neutralizing anti-CD4 binding site NAbs during HIV-1 infection
por: Sather, D, et al.
Publicado: (2009)

Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality
por: Beauparlant, David, et al.
Publicado: (2017)

Preventing escape from neutralizing antibodies
por: Brown, Matthew
Publicado: (2020)

Neutralization Interfering Antibodies: A “Novel” Example of Humoral Immune Dysfunction Facilitating Viral Escape?
por: Nicasio, Mancini, et al.
Publicado: (2012)

Oncolytic herpes simplex virus tumor targeting and neutralization escape by engineering viral envelope glycoproteins
por: Liu, Xiao-Qin, et al.
Publicado: (2018)

Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth
por: Murphy, Megan K., et al.
Publicado: (2013)

P13-06. DARPin-based microbicide strategies to block HIV entry
por: Mann, A, et al.
Publicado: (2009)

Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine
por: Keck, Mei-Le, et al.
Publicado: (2018)

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
por: Muecksch, Frauke, et al.
Publicado: (2021)

Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways
por: Zhao, Fangzhu, et al.
Publicado: (2022)

Different Infectivity of HIV-1 Strains Is Linked to Number of Envelope Trimers Required for Entry
por: Brandenberg, Oliver F., et al.
Publicado: (2015)

Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2013)

HIV-1 replication activates CD4(+) T cells with specificities for persistent herpes viruses
por: Haas, Anna, et al.
Publicado: (2010)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation
por: Fafi-Kremer, Samira, et al.
Publicado: (2010)

OA02.09. Evaluation of varatika bhasma for its ulcer protective effect on albino rats.
por: Bhatt, Paritosh
Publicado: (2013)

Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain’s exceptional capacity for sequence variation
por: Brandenberg, Oliver F, et al.
Publicado: (2014)

Delta-Omicron recombinant escapes therapeutic antibody neutralization
por: Duerr, Ralf, et al.
Publicado: (2023)

Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies
por: Dieltjens, Tessa, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_nig4m9ot61mvevemf2vrgi39mi